Suchergebnisse - (Subject:"ritonavir")

PubPharm (9)

1

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I) : a randomised, open-label trial

enthalten in: Lancet (London, England) | 2015

von Hézode, C. | Asselah, T. | Reddy, K. | +11

CommentIn: Lancet. 2015 Jun 20;385(9986):2443-5. - PMID 25837828

2

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

enthalten in: Lancet (London, England) | 2014

von Raffi, F. | Babiker, A. | Richert, L. | +117

CommentIn: Lancet. 2014 Nov 29;384(9958):1908-10. - PMID 25103175

3

FLAMINGO : how much rosier can antiretroviral therapy get?

enthalten in: Lancet (London, England) | 2014

von Pozniak, A. | Arribas, J.

CommentOn: Lancet. 2014 Jun 28;383(9936):2222-31. - PMID 24698485

4

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO) : 48 week results from the randomised open-label phase 3b study

enthalten in: Lancet (London, England) | 2014

von Clotet, B. | Feinberg, J. | van Lunzen, J. | +77

CommentIn: Lancet. 2014 Jun 28;383(9936):2191-3. - PMID 24698484

5

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN : a randomised controlled phase III trial

enthalten in: Lancet (London, England) | 2007

von Madruga, J. | Berger, D. | McMurchie, M. | +11

CommentIn: Lancet. 2007 Jul 7;370(9581):3-5. - PMID 17617250

6

Darunavir : promising initial results

enthalten in: Lancet (London, England) | 2007

von MacArthur, R.

CommentOn: Lancet. 2007 Apr 7;369(9568):1169-78. - PMID 17416261

7

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2 : a pooled subgroup analysis of data from two randomised trials

enthalten in: Lancet (London, England) | 2007

von Clotet, B. | Bellos, N. | Molina, J. | +15

ErratumIn: Lancet. 2008 Jan 12;371(9607):116

8

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks : a randomised non-inferiority trial

enthalten in: Lancet (London, England) | 2006

von Eron, J. | Yeni, P. | Gathe, J. | +14

ErratumIn: Lancet. 2006 Oct 7;368(9543):1238

9

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies : an analysis of combined data from two randomised open-label trials

enthalten in: Lancet (London, England) | 2006

von Hicks, C. | Cahn, P. | Cooper, D. | +9

1
[1]